Does Mavyret Interact with other Medications?
Severe Interactions
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- GLECAPREVIR-PIBRENTASVIR/ATAZANAVIR; TIPRANAVIR
- GLECAPREVIR-PIBRENTASVIR/STR CYP3A4 & P-GP INDUCER;PHENOBARB
- P-GLYCOPROTEIN INHIBITORS/COLCHICINE (FOR CARDIOPROTECTION)
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (> 5 MG)
- GLECAPREVIR-PIBRENTASVIR/ATORVASTATIN;LOVASTATIN;SIMVASTATIN
- SOFOSBUVIR-VELPAT; GLECAP-PIBRENT/ROSUVASTATIN (> 10 MG)
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (>30 MG)
Serious Interactions
These medications may interact and cause very harmful effects. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- SELECTED HEPATITIS C AGENTS/EFAVIRENZ; ETRAVIRINE;NEVIRAPINE
- GLECAPREVIR-PIBRENTASVIR/DARUNAVIR; LOPINAVIR; RITONAVIR
- GLECAPREVIR-PIBRENTASVIR/CYCLOSPORINE
- GLECAPREVIR-PIBRENTASVIR/MODERATE CYP3A4 AND P-GP INDUCERS
- GLECAPREVIR-PIBRENTASVIR/ETHINYL ESTRADIOL (<= 20 MCG)
- P-GLYCOPROTEIN (P-GP) INHIBITORS/PRALSETINIB
- OATP1B3 INHIBITORS/ZAVEGEPANT
- P-GLYCOPROTEIN (P-GP) INHIBITORS/BILASTINE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/DOXORUBICIN
- P-GP INHIBITORS/RIMEGEPANT
- OATP1B1-3 INHIBITORS/BRINCIDOFOVIR
- P-GLYCOPROTEIN (P-GP) INHIBITORS/RELUGOLIX
- WEAK CYP3A4 INHIBITORS/LONAFARNIB
- P-GLYCOPROTEIN (P-GP) INHIBITORS/ORAL LEFAMULIN
- WEAK CYP3A4 INHIBITORS/ELIGLUSTAT
- GLECAPREVIR-PIBRENTASVIR/ETHINYL ESTRADIOL (> 20 MCG)
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/VENETOCLAX
- P-GLYCOPROTEIN (P-GP) INHIBITORS/COLCHICINE
- SELECTED INHIBITORS OF P-GP OR BCRP/PAZOPANIB
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (<=30MG)
- P-GLYCOPROTEIN (P-GP) INHIBITORS/TOPOTECAN
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/DABIGATRAN
Moderate Interactions
These medications may cause some risk when taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- BCRP, OATP1B1, AND OATP1B3 SUBSTRATES/ENASIDENIB
- SELECT OATP1B1-3 INHIBITORS/LETERMOVIR
- SLT MODERATE AND WEAK CYP3A4 INHIBIT/SIROLIMUS PROTEIN-BOUND
- OATP1B1-3 INHIBITORS/ATOGEPANT
- WEAK CYP3A4 INHIBITORS/UBROGEPANT
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (<= 5 MG)
- MODERATE AND WEAK CYP3A4 INHIBITORS/TACROLIMUS
- SELECT P-GP INHIBITORS/EDOXABAN (<= 30 MG)
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/BETRIXABAN
- GLECAPREVIR-PIBRENTASVIR/PRAVASTATIN
- SOFOSB-VELPAT; GLECAP-PIBRENT/ROSUVASTATIN (< OR = 10 MG)
- SELECT P-GP INHIBITORS/EDOXABAN (> 30 MG)
- SELECTED HEPATITIS C AGENTS/DIGOXIN
- P-GP AND SELECTED CYP3A4 INHIBITORS/NINTEDANIB
- P-GLYCOPROTEIN (P-GP) INHIBITORS/AFATINIB
- SELECTED P-GP AND WEAK CYP3A4 INHIBITORS/RIVAROXABAN
- CYP3A4; CYP2C8; P-GLYCOPROTEIN (P-GP) INHIBITORS/LOPERAMIDE
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/ETOPOSIDE
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.